- Home
- LBTYK vs TERN Comparison
LBTYK vs TERN Comparison
Compare LBTYK & TERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LBTYK | TERN |
|---|---|---|
| Founded | 2004 | 2017 |
| Country | | US |
| Employees | N/A | N/A |
| Industry | Cable & Other Pay Television Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 3.7B |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | LBTYK | TERN |
|---|---|---|
| Price | $12.72 | $39.19 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $48.60 |
| AVG Volume (30 Days) | 1.1M | ★ 1.8M |
| Earning Date | 01-01-0001 | 04-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 11.81 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $15.50 | N/A |
| Revenue Next Year | $2.11 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.21 | $1.87 |
| 52 Week High | $13.12 | $48.26 |
Technical Indicators
Market Signals| Indicator | LBTYK | TERN |
|---|---|---|
| Relative Strength Index (RSI) | 71.23 | 58.81 |
| Support Level | $10.73 | $37.04 |
| Resistance Level | $11.76 | $39.60 |
| Average True Range (ATR) | 0.45 | 2.34 |
| MACD | 0.08 | 0.31 |
| Stochastic Oscillator | 84.54 | 78.34 |
Price Performance
Historical ComparisonAbout LBTYK Liberty Global Ltd. Class C
Liberty Global is a holding company with interests in European telecom companies in the UK, the Netherlands, Belgium, Ireland, and Slovakia. Liberty owns the main cable network in each of these geographies and has pursued a strategy since 2016 to merge or partner with mobile network operators to be able to offer converged services. Liberty also owns minority stakes in other media, entertainment, and cloud companies.
About TERN Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.